Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Pegylation of rMETase significantly prolongs half-life and biological activity

Nov. 23, 2001

Tarceva enters new phase III trial in combination with gemcitabine and cisplatin

Nov. 23, 2001

Potential development candidates emerging from Panacea's HAAH-targeted oncology program

Nov. 23, 2001

Gemin X reports in vivo efficacy for small-molecule, cancer-specific apoptosis inducers

Nov. 23, 2001

Cancer therapeutics targeting G-quadruplexes and c-myc in development at Cyternex

Nov. 23, 2001

ImmunoGen presents new taxane-based TAPs at recent cancer meeting

Nov. 23, 2001

Inex and GSK agree to develop targeted cancer drugs

Nov. 23, 2001

Antitumor effects of COX-2-specific inhibitor JTE-522 described at Japanese meeting

Nov. 22, 2001

Atugen enters evaluation agreement with Byk Gulden

Nov. 22, 2001

Research grant awarded for isolating potential anticancer agents from mushrooms

Nov. 22, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...